Tatva Chintan Pharma Chem Announces 30th AGM on Sep 25, 2026; Key Re-appointments & Dividend Approval
Tatva Chintan Pharma Chem will hold its 30th AGM on September 25, 2026, via VC/OAVM. The agenda includes adopting FY26 financial statements, declaring dividends, and re-appointing key management personnel, including the Managing Director, for three-year terms starting February 1, 2027. The company also seeks approval to raise borrowing limits to ₹1,000 crore.
The AGM agenda includes significant decisions such as dividend declaration, re-appointment of key management personnel, and a substantial increase in borrowing limits, which can impact the company's financial strategy and governance.
The announcement is a routine corporate event (AGM notice) with standard agenda items like financial statement adoption, dividend declaration, and director re-appointments. While these are important, they do not inherently signal a significant positive or negative shift in the company's immediate outlook.
Tatva Chintan Pharma Chem Limited has announced its 30th Annual General Meeting (AGM) scheduled to be held on Friday, September 25, 2026, at 04:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
The AGM will transact several key businesses, including the adoption of Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. A significant agenda item is the declaration of dividend on equity shares for the same financial year, subject to member approval.
Furthermore, the meeting will address the re-appointment of directors. Mr. Shekhar Rasiklal Somani will retire by rotation and is eligible for re-appointment. The company also plans to seek approval for the re-appointment of Mr. Chintan Nitinkumar Shah as Managing Director for a period of three years from February 1, 2027, and Mr. Ajaykumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani as Whole-time Directors for a similar three-year term from February 1, 2027, along with the fixation of their remuneration.
Additional business includes seeking approval to increase the company's borrowing limit to ₹1,000 crore and to approve the creation of charges on the company's assets to secure borrowings. The remuneration of the Cost Auditors for the Financial Year 2026-27 will also be ratified.
The notice for the AGM, along with the Explanatory Statement, is available on the company's website. The Register of Members and Share Transfer Books will be closed from September 12, 2026, to September 25, 2026, for the purpose of the AGM. A record date of September 18, 2026, has been set for e-voting and attending the AGM. The dividend, if approved, will be paid on or after October 1, 2026, to members on record as of September 11, 2026.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.